Gland Pharma (GLAND) — Board Meeting

📢 Key Event
48th AGM approved FY26 financials and reappointed directors via e-voting

🔄 What Changed
FY26 PAT grew 47% YoY to INR 10,273 million

🔮 What's Next
None

💡 Investor Takeaway
Strong growth and approvals signal confidence in Gland Pharma's expansion strategy.

Gland Pharma held its 48th AGM on August 25, 2026 via video conference, approving FY26 financials with 14% revenue growth to INR 64,307 million, 25% EBITDA margin, and 16% PAT margin. Shareholders endorsed all resolutions, including audited statements and director reappointments, via e-voting on NSDL from August 22–24. The meeting highlighted strong US (13%) and Europe (34%) growth, 388 US ANDA filings (337 approved), and 1.7 billion annual manufacturing capacity across 11 facilities. ESG initiatives and pipeline progress underscore strategic focus on CDMO expansion and global diversification.

📄 View Original Announcement (PDF)

📊 Stock Analysis — GLAND ✨ Ask AI About This

About Gland Pharma Limited (GLAND)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹47,316.21 Cr P/E: 41.9 ROE: 10.9% ROCE: 15.2% Div Yield: 0.70%

View full GLAND stock details →

📡 Get AI alerts when GLAND files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track GLAND — Free

💡 Ask AI about this filing

"What is the valuation of Gland Pharma's CDMO segment?" "How does Gland Pharma's European growth compare to peers?" "What risks remain in its US ANDA pipeline?"

Ask AI Free →

📊 More GLAND filings

See all GLAND filings →

🔥 Also filed on 25 August 2026

EPL EPL Limited Annual Report AMANTA Amanta Healthcare Limited Annual Report ZEEL Zee Entertainment Enterprises Limited Annual Report FINKURVE Finkurve Financial Services Limited Corporate Action EPL EPL Limited Annual Report ARVIND Arvind Limited Announcement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when GLAND files new disclosures

Track GLAND filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track GLAND — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd